Immobilized Human BCMA Protein (His & hFc Tag) at 2 μg/mL (100 μL/well) can bind Human BAFF/BLyS Protein (ECD, hFc & AVI Tag), Biotinylated , the EC50 is 2-16ng/mL.

BAFF/TNFSF13B Protein, Human, Recombinant (Avi & Fc), Biotinylated is expressed in HEK293 mammalian cells with AVI and Fc tag. The predicted molecular weight is 45.6 kDa and the accession number is A0A0U5J7Q1.

Human

HEK293 Cells

TNFSF20,TALL-1,DTL,BLYS,THANK,tumor necrosis factor (ligand) superfamily, member 13b,ZTNF4,TALL1,CD257,BAFF

The Human TNFSF13B (NP_006564.1) (Ala134-Leu285) was expressed with a N-terminal AVI tag followed by a Fc region of Human IgG1 tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed..

> 90 % as determined by SDS-PAGE.

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy